Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 5/2003

01.10.2003 | Commentary

Can the stroma provide the clue to the cellular basis for mammographic density?

verfasst von: Ruth Warren, Sunil R Lakhani

Erschienen in: Breast Cancer Research | Ausgabe 5/2003

Einloggen, um Zugang zu erhalten

Abstract

Mammographic density is recognised as a useful phenotypic biomarker of breast cancer risk. Deeper understanding is needed of the cellular basis, but evidence is limited because of difficulty in designing studies to validate hypotheses. The ductal epithelial components do not adequately explain the physical and dynamic features observed. The stroma is thought to interact with ductal structures in cancer initiation. Stromal tissues might account for the mammographic features, and this interplay can be hypothesised to relate risk to density. In a paper in this issue of Breast Cancer Research, Alowami has shown a relationship between density and stromal proteins, which might provide useful insight into mammographic density.
Literatur
1.
Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson P: Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003, 5: R129-R135. 10.1186/bcr622.CrossRefPubMedPubMedCentral
2.
Wolfe JN: Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer. 1976, 37: 2486-2492.CrossRefPubMed
3.
Heine JJ, Malhotra P: Mammographic tissue, breast cancer risk, serial image analysis, and digital mammography. Part 2. Serial breast tissue change and related temporal influences. Acad Radiol. 2002, 9: 317-335. 10.1016/S1076-6332(03)80374-4.CrossRefPubMed
4.
Heine JJ, Malhotra P: Mammographic tissue, breast cancer risk, serial image analysis, and digital mammography. Part 1. Tissue and related risk factors. Acad Radiol. 2002, 9: 298-316. 10.1016/S1076-6332(03)80373-2.CrossRefPubMed
5.
Byrne C: Studying mammographic density: implications for understanding breast cancer [editorial; comment]. J Natl Cancer Inst. 1997, 89: 531-533. 10.1093/jnci/89.8.531.CrossRefPubMed
6.
Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, Hopper JL: Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002, 347: 886-894. 10.1056/NEJMoa013390.CrossRefPubMed
7.
Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA: Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control. 2000, 11: 653-662. 10.1023/A:1008926607428.CrossRefPubMed
8.
Atkinson C, Warren R, Bingham SA, Day NE: Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev. 1999, 8: 863-866.PubMed
9.
Sala E, Warren R, Duffy S, Welch A, Luben R, Day N: High risk mammographic parenchymal patterns and diet: a case-control study. Br J Cancer. 2000, 83: 121-126. 10.1054/bjoc.2000.1151.CrossRefPubMedPubMedCentral
10.
Sala E, Warren R, McCann J, Duffy S, Luben R, Day N: High-risk mammographic parenchymal patterns and anthropometric measures: a case-control study. Br J Cancer. 1999, 81: 1257-1261. 10.1038/sj.bjc.6690838.CrossRefPubMedPubMedCentral
11.
van Gils CH, Otten JD, Verbeek AL, Hendriks JH: Short communication: breast parenchymal patterns and their changes with age. Br J Radiol. 1995, 68: 1133-1135.CrossRefPubMed
12.
Sala E, Solomon L, Warren R, McCann J, Duffy S, Luben R, Day N: Size, node status, and grade of breast tumours: association with mammographic parenchymal patterns. Eur Radiol. 2000, 10: 157-161. 10.1007/s003300050025.CrossRefPubMed
13.
Sala E, Warren R, McCann J, Duffy S, Luben R, Day N: Mammographic parenchymal patterns and breast cancer natural history– a case-control study. Acta Oncol. 2001, 40: 461-465. 10.1080/028418601750288172.CrossRefPubMed
14.
Boyd NF, Martin LJ, Stone J, Greenberg C, Minkin S, Yaffe MJ: Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention. Curr Oncol Rep. 2001, 3: 314-321.CrossRefPubMed
15.
Bartow S, Pathak D, Mettler F: Radiographic microcalcification and parenchymal pattern as indicators of histologic 'high-risk' benign breast disease. Cancer. 1990, 66: 1721-1725.CrossRefPubMed
16.
Friedenreich C, Bryant H, Alexander F, Hugh J, Danylik J, Page D: Risk factors for benign breast biopsies: a nested case-control study in the Alberta breast screening programme. Cancer Detect Prev. 2001, 25: 280-291.PubMed
17.
Kaufhold J, Thomas J, Eberhard J, Galbo C, Trotter D: A calibration approach to glandular tissue composition estimation in digital mammography. Med Phys. 2002, 29: 1867-1880. 10.1118/1.1493215.CrossRefPubMed
18.
Lee N, Rusinek H, Weinreb J, Chandra R, Toth H, Singer C, Newstead G: Fatty and fibroglandular tissue volume in the breasts of women 20–83 years old: comparison of X-ray mammography and computer-assisted MR imaging. Am J Roentgenol. 1997, 168: 501-506.CrossRef
19.
Arthur JE, Ellis IO, Flowers C, Roebuck E, Elston CW, Blamey RW: The relationship of 'high risk' mammographic patterns to histological risk factors for development of cancer in the human breast. Br J Radiol. 1990, 63: 845-849.CrossRefPubMed
20.
Boyd NF, Jensen H, Cooke G, Lee Han H, Lockwood G, Miller A: Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Eur J Cancer Prev. 2000, 9: 15-24. 10.1097/00008469-200002000-00003.CrossRefPubMed
21.
Byrne C, Schairer C, Brinton L, Wolfe J, Parekh N, Salane M, Carter C, Hoover R: Effects of mammographic density and benign breast disease on breast cancer risk. Cancer Causes Control. 2001, 12: 103-110. 10.1023/A:1008935821885.CrossRefPubMed
22.
Kurose K, Hoshaw-Woodward S, Adeyinka A, Lemeshow S, Watson P, Eng C: Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet. 2001, 10: 1907-1913. 10.1093/hmg/10.18.1907.CrossRefPubMed
23.
Guo Y, Martin L, Hanna W, Banerjee D, Miller N, Fishell E, Khokha R, Boyd NF: Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Bio-markers Prev. 2001, 10: 243-248.
24.
White E, Velentgas P, Mandelson M, Lehman C, Elmore J, Porter P: Variation in mammographic breast density by time in menstrual cycle among women aged 40–49 years. J Natl Cancer Inst. 1998, 90: 906-910. 10.1093/jnci/90.12.906.CrossRefPubMed
25.
Colacurci N, Fornaro F, De Francisco P, Mele D, Palermo M, del Ve W: Effects of a short-term suspension of hormone replacement therapy on mammographic density. Fertil Steril. 2001, 76: 451-455. 10.1016/S0015-0282(01)01967-7.CrossRefPubMed
26.
Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, Murphy L, Roughley PJ, Watson PH: Lumican and decorin are differently expressed in human breast carcinoma. J Pathol. 2000, 192: 313-320. 10.1002/1096-9896(200011)192:3<313::AID-PATH694>3.3.CO;2-2.CrossRefPubMed
Metadaten
Titel
Can the stroma provide the clue to the cellular basis for mammographic density?
verfasst von
Ruth Warren
Sunil R Lakhani
Publikationsdatum
01.10.2003
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 5/2003
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr642

Weitere Artikel der Ausgabe 5/2003

Breast Cancer Research 5/2003 Zur Ausgabe

Research article

Mammographic density is related to stroma and stromal proteoglycan expression

Review

The diagnosis and management of pre-invasive breast disease: Pathology of atypical lobular hyperplasia and lobular carcinoma in situ

Research article

A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers

Editorial

The diagnosis and management of pre-invasive breast disease – current challenges, future hopes

Review

The diagnosis and management of pre-invasive breast disease: Radiological diagnosis

Review

The diagnosis and management of pre-invasive breast disease: Ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) – current definitions and classification

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise